Compare WhiteOak Capital Pharma and Healthcare Fund vs SBI Healthcare Opportunities Fund
WhiteOak Capital Pharma and Healthcare Fund
EquitySectoral-Pharma
SBI Healthcare Opportunities Fund
EquitySectoral-Pharma
Risk
Very High
Very High
Rating
-
5.0
Min SIP Amount
₹100
₹500
Expense Ratio
2.74
1.99
NAV
₹16.63
₹563.66
Fund Started
16 Jan 2024
04 Jun 1999
Fund Size
₹1002.75 Cr
₹5870.00 Cr
Exit Load
-
Exit load of 0.50% if redeemed within 15 days
1 Year
12.89%
11.56%
3 Year
-
20.58%
5 Year
-
15.68%
Equity
91.43%
95.53%
Cash
0.53%
4.41%
Top 10 Holdings
Name | Assets |
|---|---|
Divi's Laboratories Ltd. | 7.73% |
Sun Pharmaceutical Industries Ltd. | 6.57% |
Torrent Pharmaceuticals Ltd. | 5.78% |
Laurus Labs Ltd. | 3.61% |
Apollo Hospitals Enterprise Ltd. | 3.47% |
Cipla Ltd. | 3.40% |
Sai Life Sciences Ltd. | 3.03% |
Ipca Laboratories Ltd. | 2.66% |
Zydus Lifesciences Ltd. | 2.60% |
Neuland Laboratories Ltd. | 2.40% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.14% |
Divi's Laboratories Ltd. | 7.91% |
Acutaas Chemicals Ltd. | 5.03% |
Apollo Hospitals Enterprise Ltd. | 4.45% |
Torrent Pharmaceuticals Ltd. | 4.42% |
Cipla Ltd. | 4.40% |
Laurus Labs Ltd. | 4.05% |
Max Healthcare Institute Ltd. | 3.80% |
Aurobindo Pharma Ltd. | 3.42% |
Aster DM Quality Care Ltd. | 3.21% |
Name
-
-
Start Date
-
-
Description
The Scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies.
The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space.
Launch Date
16 Jan 2024
04 Jun 1999
